Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
Jinyao ZhangYan WangZiling LiuLin WangYu YaoYutao LiuXue Zhi HaoJianyang WangPu-Yuan XingJun-Ling LiPublished in: Thoracic cancer (2021)
This study suggests that dacomitinib demonstrated CNS efficacy in patients with EGFR TKI-naïve EGFR-mutated NSCLC in the real-world setting. The safety profile was tolerable and manageable.